Kura Oncology FY2025 EPS Forecast Reduced by Leerink Partnrs

Kura Oncology, Inc. (NASDAQ:KURA) – Analysts at Leerink Partnrs decreased their FY2025 earnings per share estimates for Kura Oncology in a research report issued on Tuesday, November 4th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings of ($2.07) per share for the year, down from their previous forecast of ($0.40). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Leerink Partnrs also issued estimates for Kura Oncology’s Q4 2025 earnings at $0.19 EPS and FY2026 earnings at ($1.71) EPS.

A number of other brokerages have also weighed in on KURA. Wedbush restated an “outperform” rating and set a $36.00 target price on shares of Kura Oncology in a research report on Monday, October 20th. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a research note on Monday, October 20th. Wall Street Zen upgraded Kura Oncology from a “sell” rating to a “hold” rating in a report on Sunday, August 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a report on Wednesday, October 8th. Finally, Guggenheim assumed coverage on shares of Kura Oncology in a report on Thursday, September 4th. They issued a “neutral” rating for the company. Ten investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

Kura Oncology Trading Up 2.2%

Shares of KURA opened at $10.16 on Friday. The firm has a market cap of $884.12 million, a P/E ratio of -4.10 and a beta of 0.35. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 6.16. Kura Oncology has a 1 year low of $5.41 and a 1 year high of $19.73. The company has a 50 day simple moving average of $9.17 and a two-hundred day simple moving average of $7.30.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.28). Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.The business had revenue of $20.75 million for the quarter, compared to analysts’ expectations of $17.48 million.

Insider Activity at Kura Oncology

In related news, insider Mollie Leoni sold 12,314 shares of the firm’s stock in a transaction on Monday, September 29th. The stock was sold at an average price of $8.94, for a total value of $110,087.16. Following the completion of the sale, the insider directly owned 158,439 shares in the company, valued at $1,416,444.66. This trade represents a 7.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Teresa Brophy Bair sold 8,805 shares of Kura Oncology stock in a transaction on Monday, September 29th. The stock was sold at an average price of $8.94, for a total transaction of $78,716.70. Following the transaction, the insider directly owned 148,043 shares of the company’s stock, valued at $1,323,504.42. The trade was a 5.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 78,058 shares of company stock worth $697,839 in the last ninety days. Corporate insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. State of Wyoming purchased a new stake in shares of Kura Oncology in the first quarter worth approximately $48,000. Tower Research Capital LLC TRC boosted its stake in shares of Kura Oncology by 471.3% during the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after purchasing an additional 9,958 shares during the period. Pallas Capital Advisors LLC grew its holdings in shares of Kura Oncology by 32.2% in the second quarter. Pallas Capital Advisors LLC now owns 13,304 shares of the company’s stock worth $77,000 after purchasing an additional 3,241 shares during the last quarter. Magnetar Financial LLC purchased a new position in Kura Oncology in the 1st quarter worth about $79,000. Finally, Brevan Howard Capital Management LP purchased a new position in Kura Oncology in the 2nd quarter worth about $80,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.